Published in Cancer Weekly, July 22nd, 2008
"Here, we investigated the mechanism of HBV pregenomic core promoter/ enhancer II (cp/EII) regulation by full-length TAp73 and its oncogenic counterpart Delta TAp73. Ectopic and endogenous expression of TAp73 leads to a significant downregulation of cp/EII activity in p53-deficient hepatoma cell lines. In contrast, overexpression of Delta...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.